利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.023 秒)

    Methods and compositions for expanding T regulatory cells
    4.
    发明授权
    Methods and compositions for expanding T regulatory cells 有权
    用于扩增T调节细胞的方法和组合物

    公开(公告)号：US07745215B2

    公开(公告)日：2010-06-29

    申请号：US11635087

    申请日：2006-12-07

    申请人： Haval Shirwan

    发明人： Haval Shirwan

    IPC分类号： C12N5/06

    CPC分类号： C07K14/70575 ,  A61K38/00 ,  A61K38/2026 ,  A61K38/2046 ,  A61K39/0008 ,  A61K47/665 ,  A61K47/6899 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/6031 ,  B82Y5/00 ,  C07K14/475 ,  C07K14/495 ,  C07K14/55 ,  C07K14/705 ,  C07K14/70532 ,  C07K2319/00 ,  C07K2319/22 ,  C12N5/0636 ,  A61K2300/00

    摘要： The present invention provides methods and compositions for expanding Treg cells ex vivo or in vivo using one or more conjugates comprising a costimulatory moiety that stimulates at least one of three signals involved in Treg cell development and/or using dendritic cells pulsed with antigens and modified to display TGF-β, or hematopoetic stem cells or bone marrow cells modified to display TGF-β. The methods and compositions are useful, for example, in the treatment and prevention of autoimmune disease, including Type 1 diabetes and in preventing foreign graft rejection, as well as to establish mixed chimerism, induce tolerance to autoantigens, alloantigens or xenoantigens, beta cell regeneration, prevention of foreign graft rejection, and treatment of a genetically inherited hematopoietic disorder.

    摘要翻译： 本发明提供用于使用一种或多种缀合物扩增Treg细胞的方法和组合物，所述共轭物包含刺激Treg细胞发育中涉及的三种信号中的至少一种和/或使用用抗原脉冲的树突状细胞中的至少一种的共刺激部分， 显示TGF-和bgr，或修饰以显示TGF-β1的造血干细胞或骨髓细胞。 所述方法和组合物可用于例如治疗和预防自身免疫性疾病，包括1型糖尿病和预防外来移植排斥反应，以及建立混合嵌合体，诱导对自身抗原，同种抗原或异种抗原的耐受性，β细胞再生 ，预防外来移植排斥反应，以及治疗遗传性遗传性造血障碍。

    Methods of immune modulation with death receptor-induced apoptosis
    6.
    发明授权
    Methods of immune modulation with death receptor-induced apoptosis 有权
    免疫调节与死亡受体诱导凋亡的方法

    公开(公告)号：US08551494B2

    公开(公告)日：2013-10-08

    申请号：US12897336

    申请日：2010-10-04

    申请人： Haval Shirwan

    发明人： Haval Shirwan

    IPC分类号： A61K39/00 ,  A61K38/18 ,  C07K14/52 ,  C07K14/525

    CPC分类号： C07K14/525 ,  A61K38/00 ,  C07K14/70575 ,  C07K2319/00

    摘要： This invention provides chimeric proteins comprising an apoptosis-inducing molecule fused to a member of a binding pair that is capable of binding to a selected cell that expresses a death receptor. When the selected cell is exposed in vivo or ex vivo to the chimeric protein, the selected cell undergoes apoptosis. The preferred embodiment is FasL protein fused to streptavidin. The methods of using the chimeric proteins are especially beneficial in causing activated lymphocytes to undergo apoptosis, thus modulating the immune response. Patients with conditions such as asthma or allergy, or patients undergoing transplantation with allogeneic or xenogeneic tissue are examples of patients who benefit from the methods of this invention.

    摘要翻译： 本发明提供了嵌合蛋白，其包含与能够结合表达死亡受体的选定细胞的结合对成员融合的凋亡诱导分子。 当所选择的细胞在体内或离体暴露于嵌合蛋白时，所选择的细胞经历凋亡。 优选的实施方案是与链霉抗生物素蛋白融合的FasL蛋白。 使用嵌合蛋白的方法特别有利于引起活化的淋巴细胞进行细胞凋亡，从而调节免疫应答。 患有哮喘或变态反应的病人，或接受同种异体或异种组织移植的患者是受益于本发明方法的患者的实例。

    Fas ligand-avidin/streptavidin fusion proteins
    7.
    发明授权
    Fas ligand-avidin/streptavidin fusion proteins 有权
    Fas配体 - 抗生物素蛋白/链霉亲和素融合蛋白

    公开(公告)号：US07927602B2

    公开(公告)日：2011-04-19

    申请号：US10202613

    申请日：2002-07-23

    申请人： Haval Shirwan

    发明人： Haval Shirwan

    IPC分类号： A61K39/00 ,  A61K39/385 ,  A61K38/00 ,  C07K14/00

    CPC分类号： C07K14/525 ,  A61K38/00 ,  C07K14/70575 ,  C07K2319/00

    摘要： This invention provides chimeric proteins comprising an apoptosis-inducing molecule fused to a member of a binding pair that is capable of binding to a selected cell that expresses a death receptor. When the selected cell is exposed in vivo or ex vivo to the chimeric protein, the selected cell undergoes apoptosis. The preferred embodiment is FasL protein fused to streptavidin. The methods of using the chimeric proteins are especially beneficial in causing activated lymphocytes to undergo apoptosis, thus modulating the immune response. Patients with conditions such as asthma or allergy, or patients undergoing transplantation with allogeneic or xenogeneic tissue are examples of patients who benefit from the methods of this invention.

    摘要翻译： 本发明提供了嵌合蛋白，其包含与能够结合表达死亡受体的选定细胞的结合对成员融合的凋亡诱导分子。 当所选择的细胞在体内或离体暴露于嵌合蛋白时，所选择的细胞经历凋亡。 优选的实施方案是与链霉抗生物素蛋白融合的FasL蛋白。 使用嵌合蛋白的方法特别有利于引起活化的淋巴细胞进行细胞凋亡，从而调节免疫应答。 患有哮喘或变态反应的病人，或接受同种异体或异种组织移植的患者是受益于本发明方法的患者的实例。

    ADJUVANT COMPOSITIONS WITH 4-1BBL
    9.
    发明申请
    ADJUVANT COMPOSITIONS WITH 4-1BBL 审中-公开
    具有4-1BBL的补充剂组合物

    公开(公告)号：US20140199347A1

    公开(公告)日：2014-07-17

    申请号：US13983940

    申请日：2012-02-07

    申请人： Haval Shirwan

    发明人： Haval Shirwan

    IPC分类号： A61K39/00 ,  A61K31/739 ,  A61K38/19

    CPC分类号： A61K39/0011 ,  A61K31/739 ,  A61K38/191 ,  A61K39/39 ,  A61K2039/55516 ,  A61K2039/55572 ,  C12N2710/20034

    摘要： Streptavidin(SA)-4-1BBL and TLR agonists such as monophosphoryl lipid A (MPL) exhibit surprising synergy as adjuvants, inducing immune responses against weak antigens. Accordingly, there are provided adjuvant compositions comprising 4-1BBL and a toll-like receptor (TLR) agonist, such as MPL, methods of inducing an immune response against an antigen in a subject, comprising administering to the subject (a) the antigen, (b) a TLR agonist and, (c) 4-1BBL, and methods of treating a tumor or a cancer in a subject, comprising administering to the subject (a) an antigen associated with the tumor or cancer, (b) a TLR agonist, and (c) 4-1BBL.

    摘要翻译： 链霉亲和素（SA）-4-1BBL和TLR激动剂如单磷酰脂质A（MPL）表现出惊人的协同作用，作为佐剂，诱导针对弱抗原的免疫应答。 因此，提供了包含4-1BBL和toll样受体（TLR）激动剂如MPL的辅助组合物，其诱导针对受试者中的抗原的免疫应答的方法，包括给予受试者（a）抗原， （b）TLR激动剂和（c）4-1BBL以及治疗受试者的肿瘤或癌症的方法，包括给予受试者（a）与肿瘤或癌症相关的抗原，（b）TLR 激动剂，和（c）4-1BBL。

    IMMUNE MODULATION WITH DEATH RECEPTOR-INDUCED APOPTOSIS
    10.
    发明申请
    IMMUNE MODULATION WITH DEATH RECEPTOR-INDUCED APOPTOSIS 有权
    免疫调节与死亡受体诱导的疫苗

    公开(公告)号：US20110081369A1

    公开(公告)日：2011-04-07

    申请号：US12897336

    申请日：2010-10-04

    申请人： Haval Shirwan

    发明人： Haval Shirwan

    IPC分类号： A61K39/00 ,  A61K38/16 ,  A61P11/06 ,  A61P3/10 ,  A61P19/02 ,  A61P37/06 ,  C12N5/02

    CPC分类号： C07K14/525 ,  A61K38/00 ,  C07K14/70575 ,  C07K2319/00

    摘要： This invention provides chimeric proteins comprising an apoptosis-inducing molecule fused to a member of a binding pair that is capable of binding to a selected cell that expresses a death receptor. When the selected cell is exposed in vivo or ex vivo to the chimeric protein, the selected cell undergoes apoptosis. The preferred embodiment is FasL protein fused to streptavidin. The methods of using the chimeric proteins are especially beneficial in causing activated lymphocytes to undergo apoptosis, thus modulating the immune response. Patients with conditions such as asthma or allergy, or patients undergoing transplantation with allogeneic or xenogeneic tissue are examples of patients who benefit from the methods of this invention.

    摘要翻译： 本发明提供了嵌合蛋白，其包含与能够结合表达死亡受体的选定细胞的结合对成员融合的凋亡诱导分子。 当所选择的细胞在体内或离体暴露于嵌合蛋白时，所选择的细胞经历凋亡。 优选的实施方案是与链霉抗生物素蛋白融合的FasL蛋白。 使用嵌合蛋白的方法特别有利于引起活化的淋巴细胞进行细胞凋亡，从而调节免疫应答。 患有哮喘或变态反应的病人，或接受同种异体或异种组织移植的患者是受益于本发明方法的患者的实例。